KCAS’ expansion and update of our facility is setting the stage for adding services and platforms, increased throughput, and the ability to attract the best talent to join our team.”
Kansas City, Kan. (PRWEB) October 18, 2017
KCAS Bioanalytical and Biomarker Services announces several key developments including facility renovations, team expansion, and implementation of systems and software.
KCAS launched facility improvements in 2016 by engaging ARCO National Construction – KC, Inc., a full service design/build general contractor. The multi-million dollar investment to the 33,000 square feet headquarter facility begins in October and will double large molecule and cell culture areas, update and streamline small molecule and alkaline hematin lab spaces to maximize production, and expand and modernize lobby, conference rooms, and office areas.
In the past year, KCAS has grown by more than 20 percent bringing their current staff to 90, with an additional 15 percent growth in head count expected by the end of 2017. Most growth has been in large molecule and biomarker services, information technology, and sample logistics. Earlier this year, KCAS was named by Ingram’s Business Magazine as one of the fastest growing companines in Kansas City.
In addition to new instrumentation, KCAS is investing in strategic technologies to stay at the forefront of innovation. In early 2018, KCAS will implement a new bioanalytical laboratory information management system (LIMS) to further improve its data capture and management capabilities. This will position the organization to capitalize on resources, and shorten turn-around time for customers in support of large global studies.
“KCAS’ investments are positioning the organization to offer what our clients expect in a bioanalytical service provider: reliable and focused expertise, superior service over one-stop shops, and the capacity to support the demands of increasing workloads. KCAS’ expansion and update of our facility is setting the stage for adding services and platforms, increased throughput, and the ability to attract the best talent to join our team,” stated John Bucksath, CEO.
KCAS Bioanalytical & Biomarker Services is a contract laboratory with 38+ years of bioanalytical expertise. Centrally located in Kansas City, KCAS provides small- and large-molecule PK, immunogenicity, and biomarker analysis operating a variety of equipment platforms to service a wide range of therapeutic areas. KCAS’ team leverages a highly scientific staff with an average tenure of 10 years at the company to provide clients of all sizes with expertise in robust assay development, validation, and sample analysis under fit-for-purpose Non-GLP, GLP, and GCP conditions for discovery, preclinical and clinical studies. Our teams have developed and validated more than 5,500 bioanalytical assays and have undergone 16 FDA inspections. Learn more at: http://www.kcasbio.com